MannKind on hold by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh rated MannKind Corp. at hold. Walsh is encouraged by the two-year 030 safety trial. Enrollment in the trial is completed ahead of the analyst's year-end 2006 expectation. Look for positive 014 data to be presented this week. The company also completed patient enrollment in its pivotal long-term Technosphere Insulin phase 3 safety trial. Shares of the Valencia, Calif.-based biopharmaceutical company were up 19 cents, or 1.05%, at $18.21. (Nasdaq: MNKD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.